Join collection
Hello, welcome to our official website!
中国互联网保险发展简史
2019-01-12

之前的文章提到了互联网+保险是大势所趋,那么中国的互联网保险是如何从萌芽发展,到现在的欣欣向荣。今天就来探讨一下中国互联网的发展简史。

一般来说,中国互联网保险行业的发展截止目前可分为:萌芽期,起步期,探索期,积累期,发展期,爆发期。

互联网保险的兴起,归根结底是消费者日益增值的投保需求与线下保险行业不够完善的发展之间的冲突引发的。国内消费者的保险意识,保险理念随着经济的提升有了本质上的变化。从之前的听到保险就怕,就退,逐步转化为希望主动了解保险,主动投保。而由于线下理赔慢,产品不够丰富等原因,消费者不再满足线下的保险产品与服务,于是乎互联网保险应运而生。

filename

互联网保险发展萌芽期:1997~2004 年。该阶段,互联网保险以宣传和科普为主。

1997 年底,中国保险信息网诞生,是我国**面向保险市场和保险公司内部的专业中文网站,也是我国保险行业*早的第三方网站;2000 年 3 月,“ 网险网” **实现了网上投保功能;2001 年 3 月,太平洋保险开通“ 网神”,开始了真正意义上的互联网保险业务,推出 30 多个险种。

此阶段互联网保险作为销售代理而存在,各大保险公司都建立了自己的官方网站,发布保险产品的相关信息,但由于互联网金融规章制度尚未健全,法治环境尚不成熟,人们对于互联网保险的认识也存在很多不足,互联网保险对于保险公司业务发展的作用并不明显,主要起到宣传及普及保险知识的作用,此时互联网保险处于萌芽期。

深化探索期:2005~2011 年,该阶段保险公司开始探索电商营销新模式

2005年是中国互联网发展有里程碑意义的一年,这一年4 月正式实施的《*******电子签名法》标志着互联网保险进入加速发展阶段。截至 2009 年底,互联网保费收入规模达到 77.7 亿元。诸如慧择网、向日葵网、优保网等保险网站纷纷涌现,作为互联网保险中介提供保险咨询及产品销售服务。

此阶段,随着互联网用户的迅速增多,人们越来越倾向于通过互联网来获取金融保险产品和服务,同时各保险机构也致力于通过创新实现新的网络渠道的营销,逐步探索保险电子商务营销方式。

积累发展期:2012~2013 年 该阶段互联网保险实现了跨越式发展

自 2012 年中国保监会开始实施《保险代理、经纪公司互联网保险业务监管办法》,标志着互联网保险走向专业化以及规范化,互联网保险业务发展秉承透明化和信息化的原则。2012 年 8 月之后,多家公司有了更进一步的行动:平安人寿发布“ 平安人寿 E 服务” APP 客户端;国华人寿通过“ 淘宝聚划算” 销售平台推出 3 款产品,短短 3 天时间内就实现了 1.05 亿元保费收入;泰康人寿则分别与携程、淘宝等互联网平台合作打造互联网保险销售平台,取得了较好成效。2013 年出现了各种互联网金融的创新,被称为互联网金融元年。其中,2013 年 6 月推出的专为个人用户打造的余额增值服务——余额宝,既有支付宝的电子支付的功能,又有货币基金的理财功能,从运营之日起规模迅速膨胀,截至 2014 年 2 月 14 日,规模突破 4000 亿元。互联网金融理念渐渐深入人心,也逐步显现出巨大的影响力。 2013 年 11 月 6 日,由阿里巴巴、中国平安、腾讯公司共同筹资建立的“ 众安在线” 财产保险有限公司正式开业,标志着我国互联网保险进入机构专营阶段。同年,淘宝理财频道**参与“ 双十一” 活动,保险产品成为新主角。

一阶段的互联网保险通过创新实现了跨越式发展,基于电子商务及信息技术的发展需求开发了与此相宜的保险险种(如退货运费险、游戏账号装备险、微信支付安全险等),主要依托第三方电子商务平台、保险公司官方网站、保险超市等多种方式,逐步探索出其特有的业务管理模式,从而更好地为投保人提供专业服务,打造优质体验。

filename

爆发期:2014 年至今 该阶段互联网保险迎来了全面爆发

2014 年 8 月 13 日,“ 新国十条” 的颁布给保险业未来转型升级勾勒了新蓝图,支持保险公司积极运用现代互联网技术进行创新,云计算、大数据等技术无疑会带来更多可能和无限潜力。可见,互联网保险不仅仅是保险销售渠道的转变、升级,更是适宜保险产品的更新换代。互联网保险需依照互联网的规则与模式,改变现有的保险产品、服务及运营方式,并非简单地把传统的保险产品移植到网上,而是需要重新构造互联网保险关联各方的价值体系和运作逻辑,开发出适合互联网消费群体的保险产品

从销售渠道来看,互联网保险销售渠道多种多样,除了官网平台、代理机构建立的销售平台,还有第三方销售平台。其一,官网自销有利于品牌的建立和推广,如中国平安建立的平安直通、泰康人寿成立的泰康在线等。其二,代理机构建立的有类似于保险超市的专业代理渠道,可以提供一站式在线服务(如慧择网),也有类似于银行代理保险产品的网络兼业代理机构。其三,第三方销售平台包括三种:电商平台、保险咨询平台和综合类平台。电商平台较为常见,随着人们网购行为的逐渐频繁,类似淘宝保险和京东保险这类方便快捷的投保平台日益得到青睐,尤其是退货运费险和产品质量退换险这类与网络购物息息相关的小额保险;保险咨询平台也得到进一步发展,如沃保网、向日葵保险网等,其可提供专家在线解答,100% 快速回答,用户可自由查询,也可参考其他用户的问题及解答;综合类平台如网易保险,是由网易公司与国内知名保险公司共同打造的一站式购险平台,涵盖健康险、旅行险、车险、意外险、家财险等各个险种,网站设有保险 10 元店、理赔指引等,为用户提供便捷**的网上保险消费体验。

图表:互联网保险不同销售渠道的特点及案例

 filename

 

从保险产品来看,具有多样性、个性化、创新特色的互联网保险产品层出不穷。一方面诸如“ 脱单险”“ 赏月险”“ 雾霾险”“ 手机碎屏险” 等这类有新意的趣味保险在一定程度上引起了市场关注和热议,但另一方面,这些表面上的产品创新并不持久,会不断被新生事物所代替,导致产品营销并未超过宣传热度。总体上来说我国的互联网保险产品有了一定程度上的创新,但还是以线上销售线下产品为主,还需有更具突破性的创新模式。 从客户资源来看,网民的大量涌现带来了电子商务的迅猛发展,消费者有了新的消费习惯。埃森哲(Accentare)2014 年调查显示,中国受访者中有 93% 表示已准备好网上购买保险产品与服务,有 76% 已在使用智能手机与各种平台的提供商进行沟通。由此可见,互联网平台带来的客户资源及产品需求巨大,同

时这也会带来很多潜在的行业竞争者,导致竞争加剧。

从技术层面来看,大数据的运用有助于掌握准确的客户信息,网络技术使得互联网对保险公司的意义远不止于提供销售平台,其更大的功能在于通过先天的信息收集及分析优势,掌握全方位资讯,解读客户行为及心理,准确判断客户需求。因此,保险业需要紧跟时代步伐,在应用大数据时保持开放和积极的态度,遵循客户至上的理念,否则宝贵的客户资源和核心技术都可能会成为互联网企业的囊中之物。

filename

互联网保险发展至今,越来越多的产品和技术的出现,给整个行业带了活力和机遇,同时也迎来了更多的困难和挑战。如何应对日益增多的新渠道投诉?如何真正的做到产销分离?新入场者会带来哪些变革?

启明星在线作为专注于互联网保险的咨询的公司,将在接下来的文章中为您带来更详尽的分析。(编辑:启明星在线)



暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online